Just published by Michail ignatiadis Elisa Agostinetto et al in #JCOPO : ctDNA is associated w disease relapse in early #BreastCancer & allows for post-therapy risk stratification & prediction of disease recurrence in pts w early-stage breast cancer 👉 fal.cn/3sSt6 #bcsm #bcam

'Systemic therapy for early-stage breast cancer: learning from the past to build the future'. New Review by Elisa Agostinetto Joseph Gligorov & Martine Piccart now live online. Institut Jules Bordet Instituut Sorbonne Université Inserm
#breastcancer #bcsm

Elisa Agostinetto NatureRevClinOncol Institut Jules Bordet Instituut Sorbonne Université Inserm OncoAlert congratulations !

Elisa Agostinetto NatureRevClinOncol Institut Jules Bordet Instituut Sorbonne Université Inserm OncoAlert congratulations Elisa Agostinetto ! very nice to read

Congrats Elisa 😉

Elisa Agostinetto NatureRevClinOncol Institut Jules Bordet Instituut Sorbonne Université Inserm OncoAlert Congrats Elisa Agostinetto & team ✨

Indeed, we can learn important lessons from the past to build our future.

The #breastclinic Institut Jules Bordet Instituut celebrating #PinkOctober 2022 - fighting #breastcancer #bcsm Guilherme Nader Marta Elisa Agostinetto Diogo Martins Branco Véronique Debien ChiaraMolinelli @flajacobs Christos Sotiriou Michail ignatiadis Andrea Gombos Laurence Buisseret Lissandra Dal Lago Philippe Aftimos, MD OncoAlert Belgian Society of Medical Oncology

👀 Check out what’s popular this week in #JCOPO :

Circulating Tumor DNA After Neoadjuvant Chemotherapy in #BreastCancer Is Associated With Disease Relapse 👉 fal.cn/3sxTj Elisa Agostinetto Matteo Lambertini, MD PhD Michail ignatiadis #ctDNA #bcsm

#OpenAccess paper on liquid biopsies after neoadjuvant tx in #BreastCancer in Journal of Clinical Oncology 👇🏼

41 patients - 22/38 w baseline ctDNA
8 relapses - ctDNA positivity after CTX & last follow-up associated with relapse.

#@OncoAlert 🚨 #PrecisionMedicine

ascopubs.org/doi/pdf/10.120…

Celebrating #PinkOctober at Institut Jules Bordet Instituut to prevent and fight against #BreastCancer 🎀 #BreastCancer AwarenessMonth Evandro de Azambuja Véronique Debien @flajacobs ChiaraMolinelli Diogo Martins Branco Guilherme Nader Marta

The VJ Oncology post-ESMO 2022 #BreastCancer Session w/ Elisa Agostinetto & Evandro de Azambuja

Don’t miss an expert discussion on the highlights from #ESMO22 and their impact on clinical practice 🩺

7-Oct | 6PM BST / 1PM EDT / 10AM PDT

#BCsm #VJSessions ESMO - Eur. Oncology

Check our new work: 1. CtDNA detection AFTER neoadj chemo or at follow-up but NOT at baseline is associated with relapse in BC. 2. In multifocal tumors, ctDNA assays based on one tumor foci only may not capture the relapsing clone. ⁦OncoAlert⁩ ⁦ ascopubs.org/doi/full/10.12…

Let’s now build some trials in the adjuvant setting enriched with these patients with high risk! #bcsm

Does ctDNA🧬detection predict recurrence in patients with early #breastcancer ? Our study now out in JCO Precision Oncology provides an additional step in understanding the role of #liquidbiopsy 🩸to early detect disease relapse‼️
Michail ignatiadis Natera Oncology
ascopubs.org/doi/full/10.12…